Mannose-capped lipoarabinomannan (ManLAM) is considered an important virulence factor of Mycobacterium tuberculosis. However, while mannose caps have been reported to be responsible for various immunosuppressive activities of ManLAM observed in vitro, there is conflicting evidence about their contribution to mycobacterial virulence in vivo. Therefore, we used M. bovis BCG and M. tuberculosis mutants that lack the mannose cap of LAM to assess the role of ManLAM in the interaction of mycobacteria with the host cells, to evaluate vaccineinduced protection and to determine its importance in M. tuberculosis virulence. Deletion of the mannose cap did not affect BCG survival and replication in macrophages, although the capless mutant induced a somewhat higher production of TNF. In dendritic cells, the capless mutant was able to induce the up-regulation of co-stimulatory molecules and the only difference we detected was the secretion of slightly higher amounts of IL-10 as compared to the wild type strain. In mice, capless BCG survived equally well and induced an immune response similar to the parental strain. Furthermore, the efficacy of vaccination against a M. tuberculosis challenge in low-dose aerosol infection models in mice and guinea pigs was not affected by the absence of the mannose caps in the BCG. Finally, the lack of the mannose cap in M. tuberculosis did not affect its virulence in mice nor its interaction with macrophages in vitro. Thus, these results do not support a major role for the mannose caps of LAM in determining mycobacterial virulence and immunogenicity in vivo in experimental animal models of infection, possibly due to redundancy of function.
Introduction
The cell envelope of M. tuberculosis is considered a major determinant of virulence in this global pathogen. A major component of the cell envelope of all mycobacteria is lipoarabinomannan (LAM) (Briken et al., 2004; Chatterjee et al., 1998; Gilleron et al., 2008; , which appears to play a key role in the interaction with the host, and modulation by the bacterium of the host response (Briken et al., 2004; Gilleron et al., 2008; Mishra et al., 2011; Nigou et al., 2002; Nigou et al., 2003) . This complex molecule of approximately 17 kDa is the largest member of a series of lipoglycans of varying size based on a conserved mannosylphosphatidyl-myo-inositol anchor. In slow growing mycobacteria, such as M. tuberculosis, the presence of one to three mannopyranosyl residues linked to the non-reducing ends of the arabinan domain constitute the mannose cap of LAM (ManLAM), while in fast-growing mycobacteria, such as Mycobacterium smegmatis, this latter domain is capped with phosphoinositol residues (PILAM) and in some species like M. chelonae, no such capping motif is present (Guerardel et al., 2002) . The proportion of LAM non-reducing termini that are capped with mannose varies among different species of slow-growing mycobacteria and among strains of M. tuberculosis, with fully virulent M. tuberculosis laboratory strains having up to 70% capping (Chatterjee et al. 1992 , Khoo et al., 1995 . The number of mannose residues per cap is also variable even within LAM from the same species or strain .
A large number of studies have assigned a role in virulence to LAM. Initial studies aiming at determining the role of LAM in mycobacterial virulence addressed the in vitro effects of the purified molecules. These studies showed that LAM from M. tuberculosis is able to alter macrophage functions associated with protective immunity (Chan et al., 1991; Fratti et al., Accepted Article © 2012 Blackwell 1 Publishing Ltd 2003; Kang et al., 2005; Pathak et al., 2005; Sibley et al., 1988) . It was additionally shown that LAM from mycobacteria of different virulences have different immuno-modulatory activities (Adams et al., 1993; Bradbury et al., 1993; Chatterjee et al., 1992; Knutson et al., 1998; Roach et al., 1993; Vergne et al., 2003; Yoshida et al., 1997) . Numerous studies have so far suggested a role of ManLAM in binding to and in modulating the function of macrophages and dendritic cells (Chan et al., 1991; Fratti et al., 2003; Geijtenbeek et al., 2003 , Kang et al., 2005 Maeda et al., 2003; Nigou et al., 2001; Schlesinger, 1993; Schlesinger et al., 1994; Sibley et al., 1988; Tailleux et al., 2003; Torrelles et al., 2006; Vergne et al., 2003; Welin et al., 2008 ).
The studies above have led to the conclusion that ManLAM is an important virulence factor in tuberculosis, and that mannose capping plays an essential role. However, interpretation of these experiments is complex, with the experiments comparing ManLAM from fully virulent M. tuberculosis either with ManLAM from strains with a lower proportion of mannose capping, or with PILAM (Khoo et al., 1995) . It is therefore important to carry out experiments directly comparing LAM produced by isogenic strains differing only in their terminal mannosyl decoration.
Enzymatic removal of mannose residues with α-mannosidase revealed that the inhibition of IL-12 secretion by human dendritic cells caused by BCG ManLAM is strictly dependent on an intact molecule (Nigou et al., 2001) . However, to unambiguously study the role of mannose capping of LAM in an infectious setting, we have been using genetically engineered mutants in which the cap is not added. A mannosyltransferase encoded by the M. tuberculosis capA gene (rv1635c) is responsible for the addition of the first mannose residue of the mannose cap in an α(1→5) linkage (Dinadayala et al., 2006) . Previously, we identified homologous enzymes in M. marinum and M. bovis BCG (Appelmelk et al., 2008) . Disruption of the capA gene resulted
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© 2012 Blackwell 1 Publishing Ltd in bacteria deficient in the biosynthesis of the mannose cap of LAM (Appelmelk et al., 2008; Dinadayala et al., 2006 (Appelmelk et al., 2008) , we obtained the surprising result that there was no evidence for an altered host-pathogen interaction, and that capless M. marinum and BCG mutants were not less virulent than their respective parent strains. Thus, the data obtained with live isogenic strains were discrepant with the mass of data obtained earlier with purified ManLAM.
Here we follow up on our previous study of the role of the mannose cap further using isogenic strains differing only at the capA locus: we (1) look at the role of the mannose cap in the protective efficacy of BCG in vaccination studies, and (2) extend our studies on virulence to look at M. tuberculosis itself.
M. bovis BCG, the vaccine for tuberculosis protects well against disseminated TB, including meningitis in childhood, but protection against adult pulmonary TB is highly variable, ranging from 80% to no protection at all (reviewed by Colditz et al., 1994) , and a more effective vaccine is therefore required. As ManLAM has been reported as blocking phagolysosome fusion, and/or inducing IL-10, and LAM lacking mannose caps does not exhibit these activities, we hypothesized both that a capless mycobacterium would induce a different type of immune response, being less immunosuppressive and thus more protective.
We have therefore tested a capless BCG as a vaccine both in a low-dose challenge model in mice, in contrast to the high-dose challenge model used by Festjens et al. (2011) and in the guinea pig model.
Response of mouse macrophages to wild type BCG and capless BCG mutant.
Macrophages are in the first line of cellular defense against mycobacterial infection.
However, as intracellular pathogens, mycobacteria have evolved strategies to manipulate the host cell mechanisms responsible for their killing. ManLAM inhibits the maturation of phagosomes (Fratti et al., 2003; Vergne et al., 2003) and prevents macrophage activation by IFNγ (Chan et al., 1991; Sibley et al., 1988) . To assess the importance of the mannose caps in BCG survival and macrophage activation, we infected bone marrow-derived macrophages (BMDM) from Balb/c mice with either the parental BCG strain or the capless mutant strain and measured mycobacterial growth and the production of TNF and reactive nitrogen species by the macrophages. No differences in phagocytosis were observed between the mutant and parental BCG, with both BCG strains being internalized to the same extent following exposure of the macrophage monolayers to similar multiplicity of infection (MOI=2) leading to similar CFU counts at time 0 of infection, i.e. after 4 hours of contact of the macrophages with the inocula (Fig 1A) . Both strains replicated in macrophages with similar growth rates (Fig 1A) . Activation of the macrophages with IFNγ or IFNγ plus TNF caused macrophages to kill BCG but again both BCG strains behaved in the same manner (Fig 1B) . Despite the same
© 2012 Blackwell 1 Publishing Ltd degree of replication in resting macrophages and the similar bacterial loads found at the end of the experiment, the mutant induced higher amounts of TNF secretion at day 7 of infection ( Fig 1C) . The production of reactive nitrogen species was also assessed, with both BCG strains inducing the same amount (Fig 1D) . These data show that the lack of mannose caps in LAM leads to different signaling in infected macrophages but has no consequences on the ability of BCG to proliferate or survive intracellularly.
Response of mouse dendritic cells to wild type BCG and capless BCG mutant
Dendritic cells (DCs) are key players in the induction of cellular immune responses against mycobacteria (Murray, 1999) . It has been shown that ManLAM (but not non-capped LAM) prevents human DC maturation, inhibits the production of the pro-inflammatory cytokines IL-12 and TNF (Nigou et al., 2001; Nigou et al., 2002) and triggers the production of the immunosuppressive cytokine IL-10 in lipopolysaccharide (LPS)-activated DCs (Geijtenbeek et al., 2003) . To evaluate the effect of the mannose capping of LAM in the activation and modulation of DC function, we infected bone marrow-derived dendritic cells (BMDC) from Balb/c mice with the parental BCG or the mutant strain and measured the induction of co-stimulatory molecules and the production of cytokines released into the culture supernatants. Both wild type and mutant BCG activated DC and induced the same extent of up-regulation of co-stimulatory molecules (MHC-II, CD40 and CD86) (Fig. 2A) .
They also induced the secretion of the same amount of IL12p70 and TNF but, interestingly, the mutant strain induced higher amounts of IL-10 (Fig. 2B) . Thus both in macrophages and DC, mannose capping of LAM affects cytokine induction.
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As described above, ManLAM is proposed to be a key molecule in mycobacterial virulence (reviewed by Briken et al., 2004) and the mannose capping of LAM may be related to an immunosuppressive activity of this lipoglycan impacting on vaccine efficacy of BCG. We therefore wished to determine the protective efficacy of the capless BCG strain.
Before testing the protective abilities of the parent BCG and its capless mutant we compared their replication in vivo, and the immune response they induced. In order to compare the growth of wild type and capless BCG, Balb/c mice were intravenously infected with 5x10 4 CFU of either the parental strain or the capless mutant and groups of five mice were sacrificed at days 1, 10, 20, 30 and 60 post-infection. No differences in mycobacterial loads were observed for the two strains in either the spleen or the liver (Fig.3A) . In the spleen, both BCG strains proliferated until around day 20, with mice reducing the bacterial load afterwards, while in the liver, the growth of the parent and mutant strains was slowly controlled after day 10, with bacterial numbers decreasing over time, as has been classically described (Gheorghiou et al., 1985) .
We next took spleen cells from infected mice, and stimulated them in vitro with BCG antigens to assess cytokine responses. Cells from capless mutant-infected animals released the same amount of IFNγ, TNF and IL-10 as cells from mice infected with the wild type strain (Fig 3B) . No differences were found in the number of several different immune cell populations (table 1) .
Accepted Article Balb/c mice were intra-dermally inoculated with 5x10 4 CFU of the parental or the mutant strain and the dissemination of BCG to the lung and spleen was determined 70 days post-vaccination. Very low numbers of bacteria were detected in the spleen and no CFUs could be detected in the lung of both vaccinated groups (Fig 4A) , indicating a poor dissemination of BCG after intradermal inoculation. We then determined if a specific immune response could be observed in the lung of these vaccinated mice. Seventy days postvaccination, leukocytes isolated from the lungs of both immunized groups produced the same amounts of the protective cytokines IFNγ, TNF and IL-17 after in vitro re-stimulation with BCG antigens (Fig 4B) . Furthermore, both BCG strains induced the same number of CD4 + IFNγ + producing cells (Fig 4C) , showing that both the parental strain and the capless Accepted Article © 2012 Blackwell 1 Publishing Ltd mutant induce a similar type of immune response in the lung. No differences in cytokine production by spleen cells from either group were detected (data not shown).
Seventy days post-vaccination, the two groups of immunized mice and a control group of non-immune animals were subjected to a low dose aerosol challenge with a virulent strain M. tuberculosis (strain H37Rv) leading to the implantation of <100 CFU in the lung. The lungs and spleens were harvested at different time points and the numbers of CFU were determined. As expected, 30 days after the challenge with M. tuberculosis, a significantly reduced bacterial growth was observed in the lungs and spleens of vaccinated mice when compared to unvaccinated controls (Fig 4D, p<0 .001). The capless mutant induced the same level of protection as the wild type strain.
Wild type and capless BCG induce the same level of protection against a M.
tuberculosis challenge in a low dose guinea pig aerosol model.
Guinea pigs are a key TB vaccine model, as they present pathological features resembling the human disease and, like humans, express CD1b an antigen presenting molecule which is not expressed by mice and that is known to present LAM to antigenspecific T cells (Prigozy et al., 1997; Sieling et al., 1995) . Thus, potential LAM-mediated immunity may not be evident in mice, making tests in the guinea pig model prone to show differences in protection not seen in mice. We thus tested capless vs. WT BCG in a low dose aerosol challenge (10-50 CFU in the lung upon infection) in the guinea pig model. Figure 5 shows that the capless BCG is not more protective as a capped BCG.
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Isolation of a capless M. tuberculosis mutant.
The results obtained here as well as the already published information (Appelmelk et al., 2008; Festjens et al., 2011) (Parish et al., 2000) exactly as described for M. bovis BCG, including isolation of the complementant (Appelmelk et al, 2008) . Supplementary Figure 1 provides genetic evidence that indeed Rv1635c was disrupted in the mutant and that in the complementant we succeeded in the reintroduction of an intact copy of this gene.
Mild acid hydrolysis of purified LAM followed by analysis of liberated oligosaccharides by capillary electrophoresis (Nigou et al., 2000) provided evidence that all cap motifs were missing (see Supplementary Figure 2 ). We investigated if differences in glycosylation, other than the absence of the cap, were present in the knockout by two independent approaches, i.e. SDS-PAGE followed by immunoblotting with glycosylationspecific probes (Supplementary Figure 3) and, secondly, mass spectrometric analysis of isolated PIMs (Supplementary Figure 4) . No evidence for differences in glycosylation other than in the cap was found.
Accepted Article We tested the interaction of wild type and capless M. tuberculosis with Balb/c macrophages. As shown in Figure 6A the phagocytosis and growth rate of the two strains in resting BMDM was similar. The restriction of their growth in macrophages following activation by cytokines was also of the same extent ( Figure 6B ). The induction of TNF secretion and nitrite production did not differ significantly between the two strains ( Figure   6C and D) . Hence, the difference in TNF production observed in capless BCG (see Figure 7A and shows that all strains replicated to similar extents in both organs, with mice stabilizing the infection after day 60 post-infection in both the lung and the spleen at similar bacterial loads.
In addition, an identical immune response was observed for all the strains, with the production of similar amounts of IFNγ, TNF and IL-17 by spleen cells of mice with 60 days of infection (Fig. 7B) . No IL-10 was detected in culture supernatants (data not shown). We extended this study to the widely used C57/BL6 mouse strain. Mice were infected as previously described and sacrificed at days 1 and 120 post-infection. Results are expressed as
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Discussion:
The that are deficient in the biosynthesis of the mannose cap is not affected, and that a BCG mutant lacking mannose caps is as effective as a vaccine as its capped parent strain in lowdose (<100 CFU) aerosol models in mice and guinea pigs. These data are surprising since mannose capping of LAM is found in slow growing mycobacteria, amongst which are many pathogenic species, but is (almost completely) lacking in fast growing, environmental nonpathogenic species.
It has been shown in vitro that, at the level of the macrophage, purified ManLAM interferes with phagosome maturation (Fratti et al., 2003; Vergne et al., 2003) and IFNγ-dependent activation (Chan et al., 1991; Sibley et al., 1988) . ManLAM inhibits IL-12 secretion by LPS-stimulated human dendritic cells (Nigou et al., 2001 ). In addition,
ManLAM also prevents DC activation as measured by CD80, CD83 and CD86 expression and triggers secretion of IL-10 by LPS primed human DCs through DC-SIGN binding (Geijtenbeek et al., 2003) . Together these data demonstrate an immunosuppressive activity of
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Our in vitro findings comparing BCG with isogenic capless BCG showed that mannose capping of LAM is not crucial for mycobacteria survival in macrophages (Fig. 1A,B) , with the capless BCG mutant growing exactly as the wild type strain both in non-activated and in activated bone marrow-derived primary murine macrophages (Fig. 1B) Our data are in agreement with two other studies where capless BCG replicated as well as its parent in either human THP-1 macrophages (Appelmelk et al., 2008) or in the murine macrophage cell line Mf4/4 (Festjens et al., 2011) . Hence, the prediction that the mannose cap of LAM would influence mycobacterial survival does not come true in mice. With regard to cytokine induction in vitro, no difference was seen for IL-12p70 (Fig. 2B) ; for TNF, a difference was seen after 7 days only ( Fig. 1C and 2B) ; in contrast to data obtained with purified ManLAM and non-capped LAM (Geijtenbeek et al., 2003) , BCG with capless LAM induced more IL-10 than parent BCG (Fig. 2B) . Also in vivo, after intravenous injection in C57/Bl6 mice ( Fig. 3), capless BCG was not attenuated as compared to parent strains, confirming earlier data following intranasal challenge in C57/Bl6 mice (Appelmelk et al., 2008) or intravenous injection in Balb/c mice (Festjens et al., 2011) . Altogether these data show that studies with live capless LAM mutant bacteria yield data conflicting with those obtained with purified LAM. This could be due to several reasons. First, to show enhanced IL-10 (Geijtenbeek et al., 2003) or decreased IL-12 (Nigou et al., 2001; Pathak et al., 2005) production by purified (Appelmelk et al., 2008; Geijtenbeek et al., 2003 , Geurtsen et al., 2009 ) and when the cap, i.e. one of the ligands, is removed, binding to DC stays fully intact as a sufficient number of back-up ligands remains available e.g., PIMs , lipomannan and glycoproteins (Pitarque et al., 2005) . We conclude that ligands other than the mannose cap determine binding to DC, and assume that a similar redundancy exists for other effects of ManLAM, such as the inhibition of phagolysosome fusion.
A major goal of our studies was to evaluate the potency of capless BCG as a vaccine in a low dose M. tuberculosis aerosol challenge model. Based on the ability of ManLAM to induce immunosuppressive IL-10 (Geijtenbeek et al., 2003) one could expect that a capless BCG might be a more effective vaccine than parent BCG. Using a high dose murine M.
tuberculosis challenge models (5x10 4 CFU intravenously or 2x10 5 CFU intratracheally), Festjens et al. (2011) showed that prior immunization with a capless BCG (10 5 CFU subcutaneously) indeed appeared to be more protective than parent BCG: mean survival time increased from 26.5 to 27.5 wk (intravenous challenge) and from 48 to 52 wk (intratracheal challenge); also after capless BCG immunization and i.v M. tuberculosis challenge, the weight loss was delayed as compared to immunization with parent BCG. However, the differences in protection between capless BCG and parent strain were small and not statistically significant (N. Festjens, pers. communication) . We reasoned, based on early experience, that differences in immune protection could become more evident in a low dose challenge model (Appelmelk et al., 1986) . The low dose aerosol M. tuberculosis infection
© 2012 Blackwell 1 Publishing Ltd model is currently considered to be the golden standard to evaluate protective efficacy of tuberculosis vaccines. In the aerogenic model, infectious doses are as low as 10-25 CFU. The outcome of our studies (Fig. 4A) is that BCG and capless BCG hardly disseminate to the spleen or lung after intradermal injection, that (Figs. 4B and C) immune parameters following immunization were similar for both vaccines, and most importantly, the capless BCG had a protective efficacy identical to its parent strain (Fig. 4D) .
A second goal was to evaluate capless BCG in a particularly susceptible host, the guinea pig, an animal species which is also able to present the glycolipid LAM to T cells.
Specialized CD1b lipid antigen presenting molecules are present in humans, but are lacking in mice. ManLAM has long been known to be presented by CD1b to antigen-specific T cells (Sieling et al., 1995) , and hence in mice protection mediated by LAM-specific CD1b-restricted T cells will not be evident. Guinea pigs in contrast express CD1b. In addition, unlike in mice, experimental tuberculosis in the guinea pigs causes caseating granulomas.
Hence, as compared to mice the guinea pig model is seen as more representative of human disease and is an essential step in human tuberculosis vaccine development. To mimic natural disease, the aerogenic challenge route was again chosen. Fig. 5 shows that no differences in protection to M. tuberculosis infection were seen in this model following vaccination with the capless BCG or the parent strain.
A final goal was to test the role in virulence of the mannose cap of M. tuberculosis, a species not tested hitherto. In vitro, we found no differences between wild type and capless M. tuberculosis with regards to replication rate in mouse macrophages, susceptibility to cytokine activated macrophages, and induction of TNF and nitrite secretion. To maximize the possibility to observe potential LAM-mediated immunomodulatory effects, we challenged
© 2012 Blackwell 1 Publishing Ltd via the aerogenic route two immunologically contrasting mouse strains, i.e., Balb/c (a Th2-skewed strain) and C57Bl/6 (a Th1-skewed strain) (see Fig. 7A and 7B, respectively).
However, in both mouse strains capless M. tuberculosis and parent strain proliferated equally well.
Altogether our data suggest that the dominant role attributed to the mannose cap of LAM, which was predominantly based on in vitro studies with purified ManLAM (Mishra et al., 2011) cannot be confirmed by in vivo studies in mice with isogenic pairs of mutants. The cap does not affect immunoprotection by BCG, nor does it affect virulence of pathogenic mycobacteria in mice. One explanation for this lack of effect is that the role of the cap might be redundant as discussed above. Still, the outcome of our studies is puzzling: we investigated, within the taxonomic tree of the genus Mycobacterium, which species expressed a mannose-capped LAM and we found it almost exclusively in slow growing species, many of which are pathogens; in fast growing, often environmental species, the cap was mostly lacking (Driessen and Appelmelk, unpublished) . This suggests evolutionary pressure to preserve the cap. It cannot be excluded that the cap albeit not relevant in the biological assay systems tested so far with live mycobacteria, may still be important for example for transmission of M. tuberculosis from one person to another. As the DC-SIGN system in humans differs strongly from that of mice (Park et al., 2001) , this aspect of tuberculosis is not accessible to animal experimentation; possibly, non-human primates mimic the human DC-SIGN system more accurately.
In short, together with two earlier studies, our novel data provide overwhelming evidence that the mannose cap of lipoarabinomannan does not dominate the interaction of mycobacteria with the three experimental animal hosts (zebrafish, mice and guinea pigs)
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Experimental procedures:
Mycobacterial strains and growth conditions:
The BCG capA mutant, lacking the mannose cap of LAM, has been described and characterized before (Appelmelk et al., 2008) . The capA mutant in M. tuberculosis H37Rv
has not been described before and was constructed in a similar way via a two-step p1NIL-pGOAL19 approach developed by Parish and Stoker (Parish et al., 2000) , leading to a markerless deletion in the gene of interest (rv1635c). In fact, exactly the same plasmids were used to genetically modify BCG and M. tuberculosis: the DNA sequences of Rv1635c and its BCG homolog are 100% identical. Briefly, after the second step (sucrose selection) of the p1NIL-pGOAL procedure fourteen colonies were picked. The presence of this deletion was investigated by PCR. Phenotypically, the lack of mannose caps was investigated in immunoblot. In this colony dot blot, eleven of the colonies were non-reactive with the capspecific Mab 55.921A (Appelmelk et al., 2008) and three were reactive. In PCR those three yielded a rv1635c product, which was absent in the other eleven colonies. We concluded that of the fourteen colonies picked, three were revertants and eleven were (markerless) mutants lacking Rv1635c. These three mutants were investigated in SDS-PAGE-Immunoblot with monoclonal antibodies (MAbs) F30-5, 183-24, and 55.92 .1A1, concanavalinA, and DC-SIGN-Fc and further evidence was obtained they missed the cap (Supplementary Figure 3) .
Finally, one of the capless colonies was further investigated in capillary electrophoresis again providing evidence the cap is missing (Supplementary Figure 2) . A complementant was also made: rv1635c was cloned into the shuttle vector pSMT3 and the construct electroporated in
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